GeneDx Holdings Corp.

As of October 24, 2025, GeneDx Holdings Corp. shows a bullish technical trend, supported by daily moving averages and Bollinger Bands, despite some mixed signals from MACD and Dow Theory, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of October 24, 2025, GeneDx Holdings Corp. shows a bullish trend overall, supported by daily moving averages and Bollinger Bands, despite some mixed signals in shorter time frames and a mildly bearish weekly MACD.

As of October 24, 2025, GeneDx Holdings Corp. shows a bullish trend with strong daily moving averages and positive Bollinger Bands, despite some mixed signals in weekly and monthly indicators, and has significantly outperformed the S&P 500 with a year-to-date return of 67.67%.

As of October 17, 2025, GeneDx Holdings Corp. is considered undervalued with attractive valuation metrics despite a negative P/E ratio, showing significant growth potential compared to peers like Aveanna Healthcare, and has outperformed the S&P 500 with a 115.96% return over the past year.

As of October 17, 2025, GeneDx Holdings Corp. is considered undervalued with attractive valuation metrics, including a Price to Book Value of 7.99 and an EV to Sales ratio of 5.92, despite high EV to EBITDA ratios compared to peers, and has outperformed the S&P 500 with a year-to-date return of 57.35%.

As of October 17, 2025, GeneDx Holdings Corp. has shifted from a very expensive to an attractive valuation, indicating it may be undervalued despite operational challenges, with a year-to-date return of 57.35% outperforming the S&P 500's 13.30%.

As of October 3, 2025, GeneDx Holdings Corp. shows a bullish technical trend, supported by positive MACD and Bollinger Bands indicators, though there are mixed signals in longer-term indicators.

As of October 3, 2025, GeneDx Holdings Corp. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite some mixed signals from the KST and Dow Theory, and has significantly outperformed the S&P 500 over the past year and three years.

As of September 10, 2025, GeneDx Holdings Corp. has a mildly bullish technical trend, with strong weekly indicators and mixed signals from monthly metrics, while significantly outperforming the S&P 500 year-to-date and over the past year.

As of July 29, 2025, GeneDx Holdings Corp. has shifted from a risky to an attractive valuation grade, appearing undervalued with a Price to Book Value of 7.99 and an EV to Sales ratio of 5.92, despite high valuation ratios compared to peers like Aveanna Healthcare, while significantly outperforming the S&P 500 with a year-to-date return of 70.06%.

GeneDx Holdings Corp. has reported strong financial results for the quarter ending June 2025, showcasing significant achievements in operating cash flow, return on capital employed, and net sales. The company also benefited from reduced raw material costs and improved debtor turnover, indicating effective resource management and operational efficiency.

As of November 15, 2021, GeneDx Holdings Corp. is considered risky and overvalued due to negative financial ratios, including a Price to Book Value of 7.99 and an EV to EBITDA of 188.80, despite a strong recent stock performance.

As of April 30, 2025, GeneDx Holdings Corp. shows a mildly bullish technical trend, supported by daily moving averages and monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

GeneDx Holdings Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $87 million and a net loss of $7 million as of March 2025. It has a market cap of $1.83 billion and does not pay dividends.

As of Jun 18, GeneDx Holdings Corp. has a market capitalization of $1.83 billion, with net sales of $330.13 million and a net profit of -$38.57 million over the last four quarters.